-
Pfizer & Genmab's Tivdak receives US FDA full approval to treat recurrent or metastatic cervical cancer
02 May 2024 05:42 GMT
… US Food and Drug Administration (FDA) approves the … FDA to medicines that may offer significant advances in treatment … advances in effective vaccination and screening practices … of single agent chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, …
-
FDA Grants Full Approval to Tisotumab Vedotin-tftv for Recurrent, Metastatic Cervical Cancer
30 Apr 2024 22:06 GMT
… Medical Center in Miami Beach, Florida, in the news release. “Treatment … innovaTV 301 clinical trial, which demonstrated OS … the first antibody-drug conjugate with statistically … investigator’s choice of topotecan, vinorelbine, gemcitabine, irinotecan …
-
FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
29 Apr 2024 21:48 GMT
The FDA has approved tisotumab vedotin- … (n = 249), which included topotecan, vinorelbine, gemcitabine, irinotecan, or … for enrollment on the trial included having metastatic or recurrent … anti–PD-L1 agent.
Most treatment-related adverse effects (TEAEs) …
-
FDA Approves Tivdak for Metastatic Cervical Cancer
29 Apr 2024 21:47 GMT
… and Drug Administration (FDA) approved Tivdak (tisotumab vedotin-tftv) for the treatment of … findings from the innovaTV 301 trial, which included 502 patients with … chose from chemotherapy consisting of topotecan, vinorelbine, gemcitabine, irinotecan, or …
-
FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
29 Apr 2024 20:56 GMT
… controlled, multicenter, randomized trial that enrolled 502 patients … of chemotherapy consisting of topotecan, vinorelbine, gemcitabine, irinotecan … Programs for Serious Conditions-Drugs and Biologics.
Healthcare … of any medicine and device to FDA’s MedWatch …
-
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 2024 22:52 GMT
… FDA to medicines that may offer significant advances in treatment … single agent chemotherapy (topotecan, vinorelbine, gemcitabine, … clinical trial and other clinical trials with … strategic partnerships with biotechnology and pharmaceutical companies. By 2030 …
-
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 2024 22:52 GMT
… FDA to medicines that may offer significant advances in treatment … single agent chemotherapy (topotecan, vinorelbine, gemcitabine, … clinical trial and other clinical trials with … strategic partnerships with biotechnology and pharmaceutical companies. By 2030 …
-
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 2024 22:40 GMT
… FDA to medicines that may offer significant advances in treatment … single agent chemotherapy (topotecan, vinorelbine, gemcitabine, … clinical trial and other clinical trials with … strategic partnerships with biotechnology and pharmaceutical companies. By 2030 …
-
Construction of an Immunogenic Cell Death-Related Gene Signature and Genetic Subtypes for Predicting Prognosis, Immune Microenvironments, and Drug Sensitivity in Hepatocellular Carcinoma
22 Apr 2024 07:48 GMT
… doctors but also assists in formulating individualized treatment strategies, thereby improving patient treatment … drugs than the high-risk group: topotecan, … status, and pharmaceutical sensitivity. Immune infiltration … of Chinese Medicine Dongzhimen Hospital …
-
Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised
18 Apr 2024 16:54 GMT
… based chemotherapy is indicated for treatment of adult patients with metastatic … metastatic breast cancer in whom treatment with other chemotherapy options including … with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of …